284 related articles for article (PubMed ID: 29633238)
1. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
Gazzaz M; Kinzig M; Schaeffeler E; Jübner M; Hsin CH; Li X; Taubert M; Trueck C; Iltgen-Breburda J; Kraus D; Queckenberg C; Stoffel M; Schwab M; Sörgel F; Fuhr U
Clin Pharmacol Ther; 2018 Dec; 104(6):1249-1259. PubMed ID: 29633238
[TBL] [Abstract][Full Text] [Related]
2. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
3. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
5. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
7. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
[TBL] [Abstract][Full Text] [Related]
8. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
[TBL] [Abstract][Full Text] [Related]
9. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Kim MG; Kim Y; Jeon JY; Kim DS
Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
[TBL] [Abstract][Full Text] [Related]
12. Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Gravel S; Chiasson JL; Turgeon J; Grangeon A; Michaud V
Clin Pharmacol Ther; 2019 Dec; 106(6):1280-1289. PubMed ID: 31099895
[TBL] [Abstract][Full Text] [Related]
13. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
Zahir H; Kobayashi F; Zamora C; Gajee R; Gordon MS; Babiker HM; Wang Q; Greenberg J; Wagner AJ
J Clin Pharmacol; 2021 Mar; 61(3):298-306. PubMed ID: 32918831
[TBL] [Abstract][Full Text] [Related]
17. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
18. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Duthaler U; Bachmann F; Suenderhauf C; Grandinetti T; Pfefferkorn F; Haschke M; Hruz P; Bouitbir J; Krähenbühl S
Clin Pharmacokinet; 2022 Jul; 61(7):1039-1055. PubMed ID: 35570253
[TBL] [Abstract][Full Text] [Related]
19. Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.
Lin K; Zhang Q; Liu Z; Yang S; Lin Y; Wen C; Zheng Y
Int J Clin Exp Pathol; 2015; 8(5):5584-90. PubMed ID: 26191268
[TBL] [Abstract][Full Text] [Related]
20. Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
Eng H; Obach RS
Drug Metab Dispos; 2016 Aug; 44(8):1217-28. PubMed ID: 27271369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
